Natera
Leading genetic testing company providing cell-free DNA (cfDNA) testing services for prenatal screening, oncology, and organ health, serving millions of patients worldwide.
Website
https://www.natera.comLocation
Austin, Texas, USA
Founded
2004
Investors
2
Categories
genomics-sequencing, diagnostics, prenatal-testing, oncology, organ-health, cfDNA
Notes
Natera is a global leader in cell-free DNA (cfDNA) testing, providing genetic tests that help clinicians and patients make informed decisions across multiple areas of healthcare. The company's Panorama test is one of the most widely used non-invasive prenatal tests (NIPT) globally, screening for chromosomal abnormalities in pregnancy.
Listed on NASDAQ under the ticker NTRA, Natera has expanded beyond prenatal testing into oncology with its Signatera circulating tumor DNA test for cancer monitoring, and into organ health with Prospera for transplant rejection monitoring.
Team
- Steve Chapman - Chief Executive Officer
- LinkedIn: linkedin.com/in/stevechapman
- Michael Brophy - Chief Financial Officer
- Solomon Moshkevich - Chief Operating Officer
Additional Research Findings
- Founded in 2004
- Headquarters in Austin, Texas
- Listed on NASDAQ (NTRA)
- Backed by Sequoia Capital
- Panorama - leading NIPT test
- Signatera - circulating tumor DNA test for oncology
- Prospera - organ transplant rejection monitoring
- Over 3 million tests processed annually
- Global laboratory network
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sequoia Capital | Menlo Park, California, USA | generalist | seedseries-a+3 | 4 |
| Lightspeed Venture Partners | Menlo Park, California, USA | generalist | seedseries-a+3 | 3 |